EBACU (European Biotech Acquisition) Inventory-to-Revenue : 0.00 (As of Dec. 2022)

---

European Biotech Acquisition Inventory-to-Revenue Chart

---

Competitive Comparison of European Biotech Acquisition's Inventory-to-Revenue

For the Shell Companies subindustry, European Biotech Acquisition's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

---

European Biotech Acquisition's Inventory-to-Revenue Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, European Biotech Acquisition's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where European Biotech Acquisition's Inventory-to-Revenue falls into.

---

European Biotech Acquisition Inventory-to-Revenue Calculation

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

European Biotech Acquisition's Inventory-to-Revenue for the fiscal year that ended in Dec. 2022 is calculated as

European Biotech Acquisition's Inventory-to-Revenue for the quarter that ended in Dec. 2022 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

---

European Biotech Acquisition  (NAS:EBACU) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

European Biotech Acquisition's Days Inventory for the three months ended in Dec. 2022 is calculated as:

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

European Biotech Acquisition's Inventory Turnover for the quarter that ended in Dec. 2022 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

---

European Biotech Acquisition Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of European Biotech Acquisition's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Total Inventories Revenue Days Inventory Cost of Goods Sold Inventory Turnover

---

European Biotech Acquisition Business Description

Executives

Mohammad Sohail Fazeli	director	JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV
Martijn Kleijwegt	director	JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV
Volkert H. Doeksen	director	RIOUWSTRAAT 10, THE HAGVE P7 2585HA
Fernandez De Araoz Eduardo Bravo	officer: Chief Executive Officer	JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV
Koen Sintnicolaas	officer: Chief Financial Officer	JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV
Lsp Sponsor Ebac B.v.	10 percent owner	JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV
Van De Stolpe Onno	director	JOHANNES VERMEERPLEIN 9, AMSTERDAM, P7 1071 DV
Marcus Antonius Wegter	director	JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV
Lsp Management Group B.v.	10 percent owner	JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV